Retinoblastomas result from the inactivation of the RB1 gene and the loss of Rb protein, yet the cell type in which Rb suppresses retinoblastoma and the circuitry that underlies the need for Rb are undefined. Here, we show that retinoblastoma cells express markers of postmitotic cone precursors but not markers of other retinal cell types. We also demonstrate that human cone precursors prominently express MDM2 and N-Myc, that retinoblastoma cells require both of these proteins for proliferation and survival, and that MDM2 is needed to suppress ARF-induced apoptosis in cultured retinoblastoma cells. Interestingly, retinoblastoma cell MDM2 expression was regulated by the cone-specific RXRg transcription factor and a human-specific RXRg consensus binding site, and proliferation required RXRg, as well as the cone-specific thyroid hormone receptor-b2. These findings provide support for a cone precursor origin of retinoblastoma and suggest that human cone-specific signaling circuitry sensitizes to the oncogenic effects of RB1 mutations.
INTRODUCTION
Retinoblastoma is a childhood retinal tumor that has provided numerous insights into human cancer biology. For instance, retinoblastoma was one of the first malignancies to be recognized as having hereditary features, and it engendered the characterization of one of the first tumor suppressors genes to be cloned, RB1 (Weller, 1937; Friend et al., 1986) . In turn, the retinoblastoma protein, Rb, was found to have crucial roles in cell-cycle control and differentiation, and to govern a signaling pathway that is inactivated in most if not all human cancers (Weinberg, 1995; Cobrinik, 2005; Skapek et al., 2006) . However, despite the general significance of Rb in cancer biology, the basis for its crucial role in retinoblastoma pathogenesis has not been defined.
Retinoblastomas are thought to result from the inactivation of RB1, either with somatic inactivation of both RB1 alleles, or with a germline RB1 mutation and somatic inactivation of the second allele in hereditary cases. Biallelic RB1 mutations may initially result in the production of benign retinomas, with subsequent genetic changes mediating malignant transformation (Dimaras et al., 2008) . Germline RB1 mutations predispose to an average of five retinoblastomas, usually bilaterally, and with most forming in the first year (Abramson and Gombos, 1996) , but predispose to only an $0.5% chance of developing other cancers per year (Kleinerman et al., 2005) . The exceptionally high rate of retinoblastoma arising from the minuscule retinal cell population implies that the tumors derive from a cell type that is unusually sensitive to the loss of Rb function.
One way that a cell may be sensitized to the loss of Rb is by having signaling circuitry that fails to respond to Rb loss with appropriate countermeasures. Indeed, at least two cellular responses to Rb loss impede tumorigenesis in other settings, but evidently fail to do so in the cells from which retinoblastomas arise. First, in diverse settings including explanted mouse retinas, Rb loss is compensated by increased expression of the Rb-related p107 . Second, loss of Rb can deregulate E2F transcription factors and elicit E2F-dependent apoptosis (Chen et al., 2007) . Among other effects, deregulated E2Fs induce expression of a CDKN2A isoform that encodes ARF, which inhibits MDM2 and promotes p53-mediated apoptosis (Iaquinta and Lees, 2007) . As Rb-deficient retinas and premalignant retinomas have greatly increased CDKN2A ARF expression (Laurie et al., 2006; Chen et al., 2007; Dimaras et al., 2008) , it appears that the ARF-induced apoptotic response may be impaired in early stages of retinoblastoma tumorigenesis.
To gain insight into the circuitry that sensitizes to Rb loss, we sought to relate features of retinoblastoma to human retinal development. As retinoblastomas form as early as 21 weeks of gestation (Maat-Kievit et al., 1993) , we initially sought clues to this circuitry by evaluating Rb's developmental expression pattern. We found that Rb is expressed in a cell cycle-dependent manner in retinal progenitor cells, but is not evident in the early postmitotic precursors of the different retinal neurons. However, Rb was detected in older, maturing retinal precursors, and at exceptionally high levels in maturing cone precursor cells ).
Rb's prominent expression in cone precursors was intriguing, as cultured retinoblastoma cells generally express cone markers (Bogenmann et al., 1988) , but not glial markers as was once believed (Virtanen et al., 1988) , and the tumors have cone but not rod phototransduction activities (Hurwitz et al., 1990) . In addition, retinoblastomas are topographically distributed across the retina in a pattern that mimics that of L/M cones (Munier et al., 1994) . Nevertheless, the significance of the cone circuitry has been unclear, as cone features were not consistently detected in retinoblastomas in situ, and cells with properties of other retinal cell types are also present in the tumors (Gonzalez-Fernandez et al., 1992; Nork et al., 1995) . Moreover, mice with targeted loss of Rb and Rb-related proteins produced tumors with amacrine or horizontal cell, but not cone cell, features (Robanus-Maandag et al., 1998; Chen et al., 2004; Dannenberg et al., 2004; MacPherson et al., 2004; Ajioka et al., 2007) . Thus, in the current study, we examined the relevance of cone-specific signaling circuitry to retinoblastoma tumorigenesis.
RESULTS

Widespread Expression of L/M Cone Photoreceptor Markers in Retinoblastoma Tumors
To assess the cellular phenotypes of retinoblastoma cells, we stained a panel of tumors with retinal cell type-specific markers. The panel included tumors displaying a range of differentiation states, with and without prior chemotherapy, and from bilaterally and unilaterally affected patients (Table S1 available online) .
As mature photoreceptor features were previously detected in only a subset of retinoblastomas, we initially examined whether the tumors more generally express proteins that are characteristic of immature photoreceptor precursors. These included CRX, which is specific to cones, rods, and bipolar cells (Bibb et al., 2001) ; RXRg, which is specific to cones and ganglion cells (Mori et al., 2001) ; TRb2, which is specific to cones (Ng et al., 2001) ; and NRL, which is specific to rods (Swain et al., 2001 ) ( Figures 1A-1D and S1).
CRX, RXRg, and TRb2 were detected in the vast majority of cells in each of 40 tumors, including >95% of cells in ten quantitatively evaluated samples, whereas NRL generally was not and Figures  1N and 1P ). As S and L/M opsins are transiently coexpressed in developing L/M but not S cones (Cornish et al., 2004 ) ( Figure 1O ), these findings indicate that retinoblastomas largely consist of cells that have an L/M cone precursor phenotype.
Cells within Retinoblastomas that Lack Cone Markers
Express Rb and/or Retain Wild-Type RB1 Alleles We next examined whether retinoblastoma cells also express markers of retinal neurons other than cones. In these analyses, we costained samples for cell type-specific markers and for Rb, in order to identify nonneoplastic Rb + cells. We detected no tumor cells expressing the amacrine and horizontal cell-specific syntaxin, the ganglion cell-specific Brn-3b, or the horizontal, amacrine, bipolar, and progenitor cell-specific Prox1 (Table  S2) . Occasional tumors had clusters of cells that expressed the retinal progenitor cell-and bipolar cell-specific Chx10 or the progenitor, ganglion, horizontal, amacrine, or pigment epithelium cell-specific Pax6. However, the Chx10 + and Pax6 + cells coexpressed Rb ( Figure S4 ) and were concluded to derive from the normal retina. Similarly, a cluster of cells expressing the rodspecific rhodopsin was detected in one tumor, yet these cells also coexpressed Rb ( Figure S4 ). One sample had a highly differentiated retinoma-like region in which the majority of cells expressed cone markers and <1% expressed rhodopsin ( Figure S5 ). However, these cells also seemed to be nonneoplastic, as no rhodopsin + cells costained for Ki67. Thus, in this series, neoplastic retinoblastoma cells expressed markers of cones but not other retinal neurons. We also examined retinoblastomas for expression of glial and progenitor cell markers. Each of 20 tumors had cells that coexpressed glial fibrillary acidic protein (GFAP) and nestin (Table  S2 ). The vast majority of these cells coexpressed Rb ( Figures  2A-2F ), consistent with their being nonneoplastic astrocytes or Mü ller glia. However, Rb was not detected in rare GFAP + cells ( Figure 2K ), or in rare cells that lacked both GFAP and the cone marker CRX (Figures 2A-2C Figure 2M ), reflects the limited sensitivity of the FISH assay. Table S1 ). Figures 2J-2L) .
In summary, Rb -cells that lacked the cone-related CRX, or that expressed the glial marker GFAP, generally had two RB1 alleles and were nonneoplastic, whereas Rb -cells that expressed CRX retained one RB1 allele and were the neoplastic component.
Neoplastic Cone Precursor-like Cells Propagate Retinoblastoma Tumors
While the above studies showed that retinoblastoma cells generally express cone markers, it remained possible that rare cells that lack a cone phenotype might propagate the tumors. To address this possibility, we serially engrafted primary retinoblastomas to the subretinal space of nude mice ( Figure 3A) , and examined the propagation of cone-like and non-cone-like cells, using human nuclear antigen (HuNu) as a human cell marker.
As expected, virtually all cells in the original human tumors were HuNu + . $2.7% of the cells lacked CRX ( Figures 3B and 3C ), of which the majority were likely to be glia and other nonneoplastic cells as described above. Engrafting this population resulted in tumors that had human HuNu + ,CRX + tumor cells 
The Cone Phenotype of Human but Not Mouse Retinal Tumors Correlates with Robust Rb Expression in Human but Not Mouse Cone Precursors
While the above studies showed that cone markers were prominent in human retinoblastomas, amacrine and horizontal cell markers were prominent in mouse retinal tumors that resulted from loss of Rb and Rb-related proteins (RobanusMaandag et al., 1998; Chen et al., 2004; MacPherson et al., 2004; Dannenberg et al., 2004; Ajioka et al., 2007) . To address this discrepancy, we compared retinal cell marker expression in tumors from the two species. In this analysis, the cone markers CRX and TRb2 were highly expressed in human retinoblastomas but not detected in Rb/p130-deficient mouse tumors, whereas the horizontal and amacrine markers Pax6 and syntaxin were prominent in the mouse tumors but not detected in human retinoblastomas ( Figures 4A, 4B , and S8).
The cone phenotype of human but not mouse retinal tumors was notable given that Rb was prominent in maturing human cone precursors but was not detected in immature mouse cone precursors from E14 to P5, nor in mature mouse cones (Spencer et al., 2005 , and data not shown). Thus, we determined whether Rb was induced during human but not mouse cone maturation, by evaluating human foveae at fetal week 18 (which follows the onset of L/M opsin expression at week 14.5 but precedes emergence of inner and outer segments [Hendrickson and Provis, 2006] ) and mouse retinas at P8, P12, and P16 (which brackets the onset of M opsin expression and the emergence of cone outer segments at P11 [Szel et al., 1993] (Kowalik et al., 1998; Lomazzi et al., 2002) , using an antibody (SMP14) that is specific to fulllength p53-binding MDM2 isoforms.
Remarkably, MDM2 was highly expressed in foveal cone precursors at gestational weeks 16, 18, and 21 ( Figures 5A , 5B, and 5I and data not shown). The MDM2 signal diminished in progressively more peripheral and less mature cone precursors ( Figures 5F-5I ), suggesting that MDM2 levels increase during cone cell maturation. Concordantly, MDM2 was prominent in mature cones in tumor-associated retinas from retinoblastoma patients, including cones in the far periphery ( Figures  5C, 5D , and S11). MDM2 was detected at lower levels in horizontal cells but generally was not detected in other retinal cell types ( Figure 5J and data not shown). MDM2 was also highly expressed in each of eight retinoblastomas ( Figure 5E ), despite that each of the tumors had a near diploid MDM2 copy number ( Figure S12 ).
We next examined MDM2 expression in mouse retinas, wherein combined loss of Rb1 and related genes appears to elicit amacrine or horizontal cell tumors. Little or no MDM2 was detected in immature cones from E14 to P5, in maturing cone precursors at P8, P12, and P16, or in mature cones at P42 ( Figures 5K and 5M and data not shown). While we cannot rule out that the lack of Mdm2 signal in mouse cones results from epitope masking, this seems unlikely as Mdm2 was readily detected in Prox1 + horizontal cells and at lower levels in Prox1 + amacrine cells at P14 and P42, as well as in the Prox1 + tumor cells in Rb/p130-deficient mice (Figures 5K-5O ). However, Mdm2 was not detected in immature amacrine or horizontal cells at E14 or P0 (data not shown). Thus, MDM2 was highly expressed in the human and mouse cells that resemble the retinal tumors in the two species, and particularly during their postmitotic maturation.
As tumorigenesis requires proliferative as well as survival signaling, we also examined whether postmitotic cone precursors express proliferation-related proteins. While human cone precursors lacked detectable E2F1 and cyclins D1, A2, and B, they highly expressed N-Myc. N-Myc was prominent in perifoveal cone precursors at weeks 16 and 18, and in more peripheral positions at weeks 18 and 21 ( Figures 5P-5S and data not shown) but was not detected in mature cones of the postnatal human retina or in mouse cone precursors at P0, P5, or P12 (data not shown). The N-Myc staining appeared to be specific, as two N-Myc antibodies stained cone precursor nuclei in similar retinal positions (data not shown). N-Myc was also prominent in each of eight retinoblastomas that had a near diploid MYCN copy number (Figures 5T and S12 ).
MDM2 and N-Myc Are Required for Retinoblastoma Cell Proliferation and Survival
The prominent expression of MDM2 and N-Myc in cone precursors and retinoblastoma cells suggested that these proteins might be relevant to retinoblastoma development and propagation. To evaluate this possibility, we used lentiviral short hairpin RNA (shRNA) vectors to decrease MDM2 or N-Myc expression in Y79 and early passage RB176, RB177 or RB178 cells, which lack MDM2 and MYCN amplification ( Figure S12 ).
Three shRNAs were found to decrease MDM2 mRNA and protein by $60%-70%, compared to a scrambled shRNA control, at 5 days after transduction ( Figures 6A and 6B ). Over the next 5 days, each MDM2 shRNA impaired cell proliferation and induced apoptosis, and two shRNAs increased the proportion of G0/G1 cells ( Figures 6C-6E ), whereas expression of an shRNAresistant MDM2 cDNA abrogated these effects ( Figure 6F ). These findings suggest that constitutively high MDM2 expression is crucial for retinoblastoma cell proliferation and survival.
Similarly, shRNAs that diminished MYCN expression by $40%-50% impaired proliferation and promoted cell death in retinoblastoma cultures ( Figure 6G ).
MDM2 Suppresses ARF-Induced Apoptosis in Retinoblastoma Cells
As MDM2 is a major target of the ARF-mediated oncogenic stress response, we hypothesized that MDM2 might impede ARF-induced apoptosis in retinoblastoma cells. To test this idea, we determined whether a reduction in ARF could diminish the need for MDM2. We first produced RB177 derivatives that stably expressed either of two CDKN2A ARF -specific shRNAs or a scrambled shRNA control ( Figure 6H and data not shown). The cells were then transduced with an shRNA against MDM2 ( Figure 6I ) and examined for proliferation and TUNEL staining. Interestingly, the ARF-directed shRNAs increased RB177 proliferation and abrogated the antiproliferative and proapoptotic effects of the MDM2 shRNA ( Figure 6J ), indicating that MDM2 did indeed suppress ARF-induced apoptosis.
A Human-Specific RXR Element and the Cone-Specific RXRg Regulate Retinoblastoma Cell MDM2 Expression The expression of MDM2 in human cones and retinoblastoma cells suggested that cone-specific circuitry might direct MDM2 expression during retinoblastoma tumorigenesis. To address this possibility, we searched the MDM2 P1 and P2 promoters for cone-specific control elements that were identified in an unbiased bioinformatics analysis (Danko et al., 2007) . This revealed an element in the human but not mouse P2 promoter that matched a cone-specific RXR-like element (Danko et al., 2007) at each of six invariant positions, and matched the consensus RXRg homodimer binding site (Dowhan et al., 1994) at 14 of 15 positions ( Figure 7A ). We then examined whether this human-specific element promotes MDM2 expression, using an MDM2-P2-Luc reporter gene and a mutant DRXR version that had two human-to-mouse nucleotide substitutions. Notably, the two substitutions significantly diminished MDM2-P2 promoter activity in retinoblastoma cells ( Figures 7A and 7B ). We next examined whether RXRg is important for MDM2 expression. We found that each of two shRNAs that diminished RXRg expression also reduced expression of MDM2, yet the effect was transient and MDM2 RNA subsequently increased ( Figure 7C, a and b) . The initial effect of RXRg knockdown was enhanced by the p53 inhibitor, pifithrin-a p-nitro, cyclic (Figure 7C, c) , and by p53 knockdown (data not shown), suggesting that p53 opposed the reduction in MDM2 expression. Moreover, in chromatin immunoprecipitation (ChIP) experiments, two RXRg antibodies enriched for MDM2 sequences surrounding the P2 RXR site, but not for sequences in exon 12 ( Figure 7D) . We conclude that a human-specific MDM2 promoter element and the cognate cone-specific RXRg transcription factor contribute to retinoblastoma cell MDM2 expression.
The Cone-Specific Transcription Factors RXRg and TRb2 Are Required for Retinoblastoma Cell Proliferation and Survival As RXRg was found to promote MDM2 expression and is implicated in numerous aspects of cone biology, we examined whether this factor could contribute to retinoblastoma tumorigenesis. Concordantly, RXRg knockdown dramatically impaired the proliferation and survival of Y79, RB176, and RB177 cells ( Figure 7E ). Moreover, RXRg had effects beyond regulating MDM2, as the shRNA-induced decline in MDM2 was followed by increased expression of MDM2 ( Figure 7C ) as well as other p53 target genes, including CDKN1A and 14-3-3s (data not shown).
We also examined the role of the cone-specific thyroid hormone receptor b2 isoform (TRb2) (Ng et al., 2001 ) using shRNAs directed against sequences that are specific to TRb2 or that are shared with TRb1. These shRNAs impaired proliferation of Y79, RB139, and RB176 cells and suppressed tumorigenesis when shRNA-transduced Y79 cells were engrafted to the mouse subretinal space (Figure 7F-G) . We conclude that the cone-specific TRb2 and RXRg contribute to retinoblastoma cell proliferation and survival.
DISCUSSION
Germline RB1 mutations have long been known to predispose to retinoblastoma, yet the basis for the selective predilection to retinoblastoma, as opposed to other tumors, has not been defined. In this study, we evaluated whether the underlying cellular circuitry of retinoblastoma cells might sensitize to the oncogenic effects of RB1 mutations.
Retinoblastoma Cells Resemble L/M Cone Photoreceptor Precursors
Several lines of evidence indicated that retinoblastoma cells resemble neoplastic L/M cone precursors.
First, the vast majority of cells in all tumors expressed conespecific proteins, as well as proteins that are concurrently expressed only in cones, such as CRX and RXRg. These proteins are not merely associated with the cone phenotype, but include transcription factors such as CRX, RXRg, and TRb2 that are among the earliest cone proteins to be expressed and that dictate numerous cone cell features (Furukawa et al., 1999; Ng et al., 2001; Roberts et al., 2005) . While cone-specific mRNAs and phototransduction activities were earlier detected in cultured retinoblastomas (Bogenmann et al., 1988; Hurwitz et al., 1990) , we know of only two studies that evaluated cone-specific protein expression in retinoblastomas in situ. One study reported widespread expression of cone transducin-a (Rodrigues et al., 1992) , whereas the second showed that antibodies against chicken opsins detected cells in approximately one-half of retinoblastoma samples (Gonzalez-Fernandez et al., 1992) . Our results with an anti-human L/M opsin antibody, on the contrary, demonstrate that retinoblastomas consistently exhibit features of maturing L/M cone precursors.
Second, rare cells that expressed markers of retinal neurons other than cones were found to coexpress Rb and were concluded to derive from the surrounding normal retina. Similarly, cells that expressed glial and progenitor markers generally coexpressed Rb, and rare GFAP + ,Rb -and CRX -,Rb -cells generally retained two RB1 alleles. These findings imply that the vast majority and potentially all tumor cells that lack cone markers are nonneoplastic. Finally, cone precursor-like cells propagated retinoblastoma tumors, with engraftment of as few as 100 cells sufficient to initiate tumorigenesis. Thus, cone-like cells appear to propagate the tumors in the absence of a distinct stem cell population.
We also confirmed that the human retinoblastoma phenotype differs from that of mouse tumors that develop as a consequence of the combined loss of Rb and Rb-related proteins. The distinction between the mouse and human tumors appeared to be absolute, as we found no evidence of human retinoblastoma cells that lacked cone markers, and no evidence of mouse tumor cells that expressed cone markers.
A Role for Cone Precursor MDM2 Expression in Retinoblastoma Tumorigenesis
To address whether cone precursor circuitry might contribute to retinoblastoma, we examined whether cones have distinctive circuitry that could impede an ARF-mediated apoptotic response to Rb loss. We found that the ARF target, MDM2, was expressed at exceptionally high levels in human cone precursors and suppressed ARF-induced apoptosis in retinoblastoma cells. The MDM2 expression and resistance to ARF signaling seem to ensue at least in part from cone precursor circuitry, as human MDM2 promoter activity depended upon an RXR promoter element and on the cognate RXRg protein.
Importantly, cone precursor MDM2 expression provides a rationale for the lack of classical p53 pathway mutations in retinoblastoma tumors. In most cancers, the p53 pathway is inactivated by mutation of TP53 or CDKN2A ARF or by amplification of MDM2. Moreover, these changes appear to be necessary for the tumors to avert ARF-mediated responses to oncogenic stress, rather than to avert the DNA damage response (Christophorou et al., 2006; Efeyan et al., 2006) . Thus, it has been puzzling that CDKN2A and TP53 mutations have not been detected in retinoblastoma, and that MDM2 amplification is rare (Kato et al., 1996; Schlamp et al., 1997; Laurie et al., 2006) . Our findings suggest that the ARF-mediated oncogenic stress response is inactivated in retinoblastomas because of the robust expression of MDM2, in the absence of MDM2 amplification. Nevertheless, retinoblastoma cells retain an effective p53-mediated DNA damage response (Kondo et al., 1997) and are sensitive to the MDM2 antagonist Nutlin-3a (Elison et al., 2006) , as expected for cells that rely on robust MDM2 expression.
It has also been proposed that the p53 pathway is impaired in retinoblastoma as a consequence of copy number gains of the MDM2-related gene, MDM4 (also called MDMX) on chromosome 1q32.1 (Laurie et al., 2006) . However, while MDM4 was shown to impede the p53-mediated radiation response, it was not shown to promote retinoblastoma cell survival in the absence of radiation, or to oppose ARF-mediated apoptotic signals. Moreover, a recent study suggested that a gene other than MDM4 may be a more general target of chromosome 1q gains (Dimaras et al., 2008) , and MDM4 amplification was rare in our samples ( Figure S12 ). Thus, while MDM4 copy number gains may contribute to some retinoblastomas, our findings suggest that robust expression of the unamplified MDM2 has a more general role in averting the ARF-mediated oncogenic stress response, and could act during early stages of tumorigenesis before Rb-deficient cells acquire additional genetic aberrations.
Notably, MDM2 was prominent in human but not mouse cones, yet was prominent in the horizontal cells of both species and in Prox-1 + amacrine cells in mice. The high MDM2 levels in mouse horizontal and amacrine cells is intriguing in light of evidence that mouse retinal tumors that arise due to combined Rb1 family mutations derive from apoptosis-resistant cells (Chen et al., 2004) ; specifically from horizontal cells in some genetic backgrounds (Ajioka et al., 2007) and potentially from amacrine cells in others (Robanus-Maandag et al., 1998; Chen et al., 2004) . Thus, MDM2 appears to be well situated to contribute to mouse horizontal or amacrine cell tumors upon combined loss of Rb and Rb-related proteins, and to contribute to human cone precursor-like retinoblastomas upon loss of Rb. However, MDM2 evidently does not predispose to horizontal or amacrine cell tumors upon loss of only Rb, possibly because of the redundant actions of p107 and p130 in these cell types.
Roles for Additional Cone-Specific Circuitry in Retinoblastoma
We also found that human cone precursors prominently expressed N-Myc and that retinoblastoma cells require N-Myc for proliferation and survival. The apoptotic response to N-Myc knockdown is consistent with the need for persistent Myc expression in numerous mouse tumor models, and might reflect the altered expression of diverse Myc target genes, yet continued CDKN2A ARF expression, when Myc is incompletely suppressed (Shachaf et al., 2008) . Interestingly, MYCN was amplified in a subset of mouse retinal tumors but generally is not amplified in human retinoblastomas (Corson and Gallie, 2007; MacPherson et al., 2007) . Thus, while further study is required, these observations are consistent with a role for cone precursor-related N-Myc expression in retinoblastoma tumorigenesis.
This study also revealed roles for the cone cell transcription factors RXRg and TRb2 in retinoblastoma cells. As these factors regulate opsin expression in cone precursors, but are not expressed in proliferating retinal cells (Ng et al., 2001; Roberts et al., 2005) , their postmitotic roles appear to be co-opted for proliferative purposes during retinoblastoma tumorigenesis. Moreover, our data indicate that RXRg promotes MDM2 expression in retinoblastoma cells and suggest that RXRg could likewise contribute to MDM2 expression in human cone precursors via an RXRg recognition element in the human MDM2 promoter. As the RXRg element was present in the human but not mouse promoter, this element could contribute to the uniquely human proclivity to develop cone-like retinoblastoma tumors. Likewise, our data suggest that horizontal and amacrine cell circuitry might promote Mdm2 expression and tumorigenesis in mouse retinoblastoma models.
Implications for the Retinoblastoma Cell of Origin As cone precursor circuitry was crucial to retinoblastoma cell proliferation, it is of interest to consider whether this circuitry is adopted during the course of tumorigenesis or is continuously present because of the tumor's origin from cone precursor cells.
A cone-related origin of retinoblastoma was previously suggested by the L/M cone-like distribution of the tumors over the surface of the retina (Munier et al., 1994) . This distribution is difficult to reconcile with an origin from cells that are unrelated to cones but is consistent with an origin either from cone precursors or from cone-directed retinal progenitor cells. Our results provide support for a cone precursor but not progenitor origin, as we did not detect neoplastic cells that have progenitor features in 40 retinoblastoma tumors.
It was also suggested that retinoblastomas might arise from cells that reside in the retinal inner nuclear layer (INL), rather than from outer nuclear layer (ONL) cells such as cones, based on a potentially nascent tumor that was adjacent to the INL and had INL-like nuclear morphology (Gallie et al., 1999) . However, as the tumor was almost entirely within the ONL, and its nuclear morphology has uncertain significance, this sample is also consistent with a cone precursor origin.
A cone precursor origin is also supported by the robust expression of Rb, MDM2, and N-Myc-and the abrupt decline in p27 and with Rb's ability to reassert growth control when restored to cone precursor-like retinoblastoma cells . Thus, our findings support a model in which a lack of Rb permits the aberrant proliferation of N-Myc + cone precursors, robust MDM2 expression impedes an ARF-mediated apoptotic response, and cone factors such as RXRg and TRb2 further promote cell proliferation and survival. Moreover, as Rb loss can elicit mitotic instability (Hernando et al., 2004) , the aberrantly proliferating cells could rapidly acquire additional cytogenetic changes that lead to malignancy ( Figure 7H ). As Rb, MDM2, and N-Myc are prominent in maturing but not nascent cone precursors, this model implies that contextual features that are specific to human cone maturation could impose the requirement for Rb tumor suppressor function.
Finally, a cone precursor origin accords with the prediction that human and mouse retinal tumors derive from different intrinsically death-resistant retinal precursors (Pacal and Bremner, 2006) and suggests that cell type-specific MDM2 expression may underlie the death-resistant phenotypes. Thus, while this study does not experimentally demonstrate that retinoblastomas derive from cone precursors within the developing human retina, the ability to reconcile the distinct features of the human and mouse retinal tumors further supports the cone precursor model.
In summary, this study shows that retinoblastoma cells express numerous components of the cone precursor signaling circuitry and rely upon this circuitry for their proliferation and survival. The findings appear to be consistent with a cone precursor origin of retinoblastoma and suggest that elements of the cone precursor program may provide novel targets for retinoblastoma therapy. More generally, the findings suggest that cell type-specific as well as species-specific signaling circuitry sensitizes specific cells to specific oncogenic mutations.
EXPERIMENTAL PROCEDURES
Immunostaining and FISH Retinas and retinoblastoma samples were prepared, sectioned, and immunostained as previously described and as detailed in the Supplemental Data. Some sections were imaged by confocal microscopy and probed for RB1 and a 13q34 hybridization control, and cells with immunostaining profiles of interest and two 13q34 signals examined for hybridization to RB1, as described in the Supplemental Data.
Xenografts
Two hundred thousand retinoblastoma cells were injected into the subretinal space of nude mice 1 day after explant and examined 60 days after primary and secondary grafts, 48 days after tertiary grafts, or 4-6 months after grafts of 10 4 , 10 3 , or 10 2 cells. Sections were stained for HuNu with a FITC-conjugated second antibody and for cone markers with a Cy3-conjugated second antibody. More than 8000 HuNu + cells were examined per marker.
shRNA Knockdowns Cells infected with pLKO lentiviral shRNA vectors were selected for 48-72 hr starting 48 hr after infection, plated at 2 3 10 4 cells per well for counting, attached to coverslips for immunostaining or TUNEL, or analyzed by FACS, qRT-PCR, or immunoblotting. RB177 cells transduced with pLKO shCDKN2A ARF constructs or controls were selected, reinfected with pLKO-shMDM2-377 or a control, counted on days 1 and 5, and analyzed by qRT-PCR on day 4 and by TUNEL on day 5 after infection. RB177 cells were transduced with UINZ-MDM2-sh380R or the UGINZ vector, selected in G418, and transduced with pLKOshMDM2-380 as detailed in the Supplemental Data.
Luciferase Assays
Cells were transfected with pRL-TK (Promega), P2-Luc, and P2-Luc-DRXR (as described in the Supplemental Data), and the firefly:Ranilla luciferase ratio was determined at 72 hr.
Chromatin Precipitation
Chromatin precipitation (ChIP) assays were performed with RXRg antibodies H-105 (Ab1) and Y-20 (Ab2) (Santa Cruz) and qRT-PCR as described in the Supplemental Data.
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Supplemental Data include Supplemental Experimental Procedures, 13 figures, and two tables and can be found with this article online at http:// www.cell.com/supplemental/S0092-8674(09)00400-0.
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